FTC Approves Johnson & Johnson’s $21.3B Acquisition of Synthes

The Federal Trade Commission has approved Johnson & Johnson’s $21.3 billion acquisition of Synthes but with one stipulation, according to a Washington Post report.

Advertisement

While Johnson & Johnson has been cleared to acquire Synthes, it must sell its wrist fractures unit, known as DVR, to Biomet. The FTC concluded, without this stipulation, Johnson & Johnson and Synthes would control 70 percent of the market for the wrist fracture treatment systems and harm competition.

Related Articles on Orthopedic Devices:

Mazor Launches C-Onsite Spinal Implant Verification Software on Global Scale

Premier Healthcare Alliance Announces New Agreements for Spinal Implants

Orthofix Resolves Alleged False Claims With $34M Settlement

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Spinal Tech

Advertisement

Comments are closed.